Patient Characteristics and Cytokine Genotypes With the Development of GVHD Grades III-IV
UPN . | Diagnosis . | CR . | HLA Type . | TNF − 308 . | IL-10 Genotype . | TNFd Genotype . | GVHD Occurrence . | Survival Posttransplant (mo) . | Cause of Death . |
---|---|---|---|---|---|---|---|---|---|
39 | CGL | Cy/TBI | A2 A9 (24) B7 Bw22 (55) Cw3 | F1/F1 | i13/13* | d3/d3† | III | 152 | |
40 | AML | M/TBI | A2 A30 (19) B13 B39 (16) DR17 DR8 | F1/F1 | i9/13* | d3/d3† | III | 25 | |
41 | ALL | M/TBI | A28 A30 (19) B27 B44 (12) DR1501-1503 DR0701 | F1/F1 | i11/13* | d3/d3† | III | 12 | |
42 | CGL | Bu/M | A1 A11 B5 B57 (17) DR4 DR71 (3) | F1/F1 | i12/12* | d4/d4 | III | 2 | Fungal infection |
43 | AML | M/TBI | A25 A31 B18 B40 DR2 DR4 | F1/F1 | i8/15* | d3/d3† | III | 1 | Allotoxicity |
44 | CGL | Cy/TBI | A2 A3 B8 B5 DR3 DR5 | F1/F2 | i8/13* | d1/d3 | III | 2 | GVHD and viral infection |
45 | AML | M/TBI | A2 A3 B7 DR2 DR4 | F1/F1 | 9/14* | d3/d3† | III | 59 | |
46 | ALL | Cy/TBI | A1 A3 B17 B15 DR4 DR7 | F1/F1 | i9/9 | d4/d4 | III | 107 | |
47 | AML | M/TBI | A1 A3 B8 B35 DR1 DR17 (3) | F1/F2 | i9/13* | d1/d4 | III | 122 | Nontransplant?? related death |
48 | MDS | Bu/Cy | A11 A32 B7 B4 DR4 DR7 | F1/F1 | i9/9 | d3/d3† | IV | 2 | GVHD |
49 | AML | M/TBI | A2 A29 (19) B44 (12) DR4 DR7 | F1/F1 | i10/13* | d3/d3† | IV | 2 | VOD |
UPN . | Diagnosis . | CR . | HLA Type . | TNF − 308 . | IL-10 Genotype . | TNFd Genotype . | GVHD Occurrence . | Survival Posttransplant (mo) . | Cause of Death . |
---|---|---|---|---|---|---|---|---|---|
39 | CGL | Cy/TBI | A2 A9 (24) B7 Bw22 (55) Cw3 | F1/F1 | i13/13* | d3/d3† | III | 152 | |
40 | AML | M/TBI | A2 A30 (19) B13 B39 (16) DR17 DR8 | F1/F1 | i9/13* | d3/d3† | III | 25 | |
41 | ALL | M/TBI | A28 A30 (19) B27 B44 (12) DR1501-1503 DR0701 | F1/F1 | i11/13* | d3/d3† | III | 12 | |
42 | CGL | Bu/M | A1 A11 B5 B57 (17) DR4 DR71 (3) | F1/F1 | i12/12* | d4/d4 | III | 2 | Fungal infection |
43 | AML | M/TBI | A25 A31 B18 B40 DR2 DR4 | F1/F1 | i8/15* | d3/d3† | III | 1 | Allotoxicity |
44 | CGL | Cy/TBI | A2 A3 B8 B5 DR3 DR5 | F1/F2 | i8/13* | d1/d3 | III | 2 | GVHD and viral infection |
45 | AML | M/TBI | A2 A3 B7 DR2 DR4 | F1/F1 | 9/14* | d3/d3† | III | 59 | |
46 | ALL | Cy/TBI | A1 A3 B17 B15 DR4 DR7 | F1/F1 | i9/9 | d4/d4 | III | 107 | |
47 | AML | M/TBI | A1 A3 B8 B35 DR1 DR17 (3) | F1/F2 | i9/13* | d1/d4 | III | 122 | Nontransplant?? related death |
48 | MDS | Bu/Cy | A11 A32 B7 B4 DR4 DR7 | F1/F1 | i9/9 | d3/d3† | IV | 2 | GVHD |
49 | AML | M/TBI | A2 A29 (19) B44 (12) DR4 DR7 | F1/F1 | i10/13* | d3/d3† | IV | 2 | VOD |
Characteristics and results on patients with grade III-IV GVHD showing unique patient number (UPN), diagnosis, conditioning regimes available HLA typing results, genotype for the TNF −308, IL-10 −1064, and TNFd microsatellite polymorphisms, occurrence of acute GVHD, survival, and cause of death.
Abbreviations: VOD, veno-occlusive disease; Cy/TBI, cyclophosphamide/TBI; M/TBI, melphalan/TBI. C/Bu, Busulphan; M/VP16/B, melphalan/atoposide/BCNU.
Patients who possessed an IL-10 microsatellite allele with greater numbers of dinucleotide repeats (alleles 12-15).
Patients who were homozygous for the TNFd3 allele (d3/d3).